MDVN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MDVN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Medivation's Capital Expenditure for the three months ended in Jun. 2016 was $-4.60 Mil. Its Operating Income for the three months ended in Jun. 2016 was $-625.64 Mil.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
The historical data trend for Medivation's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivation Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Capex-to-Operating-Income | Get a 7-Day Free Trial | - | - | - | 0.04 | 0.05 |
Medivation Quarterly Data | ||||||||||||||||||||
Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | |
Capex-to-Operating-Income | Get a 7-Day Free Trial | 0.10 | 0.05 | 0.03 | 1.15 | - |
For the Biotechnology subindustry, Medivation's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Medivation's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Medivation's Capex-to-Operating-Income falls into.
Medivation's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2015 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-19.459) | / | 414.613 | |
= | 0.05 |
Medivation's Capex-to-Operating-Income for the quarter that ended in Jun. 2016 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-4.604) | / | -625.641 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivation (NAS:MDVN) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Thank you for viewing the detailed overview of Medivation's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
W Anthony Vernon | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, NEW YORK NY 10018 |
Marion Mccourt | officer: Chief Operating Officer | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Tseli Lily Yang | officer: VP, Finance and Accounting | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Mohammad Hirmand | officer: Interim Chief Medical Officer | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
David Hung | director, officer: President and CEO | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Wendy L Yarno | director | |
Jennifer Jarrett | officer: Chief Financial Officer | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Kim D Blickenstaff | director | C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105 |
Powell Andrew Kenneth William | officer: SVP, General Counsel & Crp Sec | C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940 |
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Rick Bierly | officer: CFO (former) | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Joseph M Lobacki | officer: Chief Commercial Officer | C/O MICROMET, INC., 9201 CORPORATE BLVD., SUITE 400, ROCKVILLE MD 20850 |
Jennifer J Rhodes | officer: GC & Corporate Secretary | C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 09-11-2009
By GuruFocus Research GuruFocus Editor • 02-11-2011
By TipRanks TipRanks • 12-23-2014
By Tiziano Frateschi Tiziano Frateschi • 05-20-2016
By GuruFocus Research GuruFocus Editor • 02-09-2011
By Jimmy Xiao Jimmy Xiao • 01-26-2016
By TipRanks TipRanks • 02-03-2015
By TipRanks TipRanks • 03-26-2015
By GuruFocus Research GuruFocus Editor • 01-21-2010
By GuruFocus Research GuruFocus Editor • 12-09-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.